Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
44
ADMA Quote, Financials, Valuation and Earnings
Last price:
$15.57
Seasonality move
:
7.6%
Day range:
$15.84 - $16.49
52-week range:
$13.50 - $25.67
Dividend yield:
0%
P/E ratio:
19.12x
P/S ratio:
8.20x
P/B ratio:
8.99x
Volume:
1.9M
Avg. volume:
2.2M
1-year change:
2.52%
Market cap:
$3.9B
Revenue:
$426.5M
EPS (TTM):
$0.85
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$139.8M | $0.20 | 23.95% | 81.82% | $25.67 |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$111.5M | $0.09 | 49.53% | -88.43% | $31.75 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
EDIT
Editas Medicine, Inc.
|
$8.8M | -$0.21 | -71.35% | -61.06% | $5.43 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$16.28 | $25.67 | $3.9B | 19.12x | $0.00 | 0% | 8.20x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$26.59 | $31.75 | $3.3B | -- | $0.00 | 0% | 10.68x |
|
CRMD
CorMedix, Inc.
|
$7.43 | $14.86 | $585.4M | 3.62x | $0.00 | 0% | 2.50x |
|
EDIT
Editas Medicine, Inc.
|
$1.77 | $5.43 | $172.8M | -- | $0.00 | 0% | 3.25x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
SVRA
Savara, Inc.
|
$5.35 | $10.81 | $1.1B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -3.277 | 2.38% | 3.53x |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
41.85% | -0.523 | 5.02% | 3.07x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
EDIT
Editas Medicine, Inc.
|
85.41% | 2.960 | 24.32% | 2.81x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
ARQT
Arcutis Biotherapeutics, Inc.
|
$90.5M | $8.5M | -15.75% | -29.4% | 8.59% | -$1.8M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
EDIT
Editas Medicine, Inc.
|
$6.8M | -$24.5M | -149.99% | -246.73% | -325.44% | -$31.3M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
ADMA Biologics, Inc. vs. Competitors
-
Which has Higher Returns ADMA or ARQT?
Arcutis Biotherapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 7.47%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M ARQTArcutis Biotherapeutics, Inc.91.25% $0.06 $271.8M -
What do Analysts Say About ADMA or ARQT?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 57.66%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.75 which suggests that it could grow by 19.41%. Given that ADMA Biologics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 ARQTArcutis Biotherapeutics, Inc.5 1 0 -
Is ADMA or ARQT More Risky?
ADMA Biologics, Inc. has a beta of 0.485, which suggesting that the stock is 51.502% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.702, suggesting its more volatile than the S&P 500 by 70.199%.
-
Which is a Better Dividend Stock ADMA or ARQT?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or ARQT?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 19.12x while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.20x versus 10.68x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M ARQTArcutis Biotherapeutics, Inc.10.68x -- $99.2M $7.4M
-
Which has Higher Returns ADMA or CRMD?
CorMedix, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of 49.9%. ADMA Biologics, Inc.'s return on equity of 58.71% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About ADMA or CRMD?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 57.66%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 99.96%. Given that CorMedix, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe CorMedix, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 CRMDCorMedix, Inc.4 0 0 -
Is ADMA or CRMD More Risky?
ADMA Biologics, Inc. has a beta of 0.485, which suggesting that the stock is 51.502% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock ADMA or CRMD?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or CRMD?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. ADMA Biologics, Inc.'s net income of $36.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 19.12x while CorMedix, Inc.'s PE ratio is 3.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.20x versus 2.50x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M CRMDCorMedix, Inc.2.50x 3.62x $104.3M $108.6M
-
Which has Higher Returns ADMA or EDIT?
Editas Medicine, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -332.98%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Editas Medicine, Inc.'s return on equity of -246.73%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M EDITEditas Medicine, Inc.90.44% -$0.28 $92.2M -
What do Analysts Say About ADMA or EDIT?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 57.66%. On the other hand Editas Medicine, Inc. has an analysts' consensus of $5.43 which suggests that it could grow by 206.7%. Given that Editas Medicine, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Editas Medicine, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 EDITEditas Medicine, Inc.6 6 0 -
Is ADMA or EDIT More Risky?
ADMA Biologics, Inc. has a beta of 0.485, which suggesting that the stock is 51.502% less volatile than S&P 500. In comparison Editas Medicine, Inc. has a beta of 2.154, suggesting its more volatile than the S&P 500 by 115.432%.
-
Which is a Better Dividend Stock ADMA or EDIT?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Editas Medicine, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or EDIT?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Editas Medicine, Inc. quarterly revenues of $7.5M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Editas Medicine, Inc.'s net income of -$25.1M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 19.12x while Editas Medicine, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.20x versus 3.25x for Editas Medicine, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M EDITEditas Medicine, Inc.3.25x -- $7.5M -$25.1M
-
Which has Higher Returns ADMA or MRKR?
Marker Therapeutics, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of -162.11%. ADMA Biologics, Inc.'s return on equity of 58.71% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About ADMA or MRKR?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 57.66%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 438.81%. Given that Marker Therapeutics, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 MRKRMarker Therapeutics, Inc.3 0 0 -
Is ADMA or MRKR More Risky?
ADMA Biologics, Inc. has a beta of 0.485, which suggesting that the stock is 51.502% less volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock ADMA or MRKR?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or MRKR?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Marker Therapeutics, Inc. quarterly revenues of $1.2M. ADMA Biologics, Inc.'s net income of $36.4M is higher than Marker Therapeutics, Inc.'s net income of -$2M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 19.12x while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.20x versus 3.96x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M
-
Which has Higher Returns ADMA or SVRA?
Savara, Inc. has a net margin of 27.14% compared to ADMA Biologics, Inc.'s net margin of --. ADMA Biologics, Inc.'s return on equity of 58.71% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About ADMA or SVRA?
ADMA Biologics, Inc. has a consensus price target of $25.67, signalling upside risk potential of 57.66%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 102.1%. Given that Savara, Inc. has higher upside potential than ADMA Biologics, Inc., analysts believe Savara, Inc. is more attractive than ADMA Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ADMAADMA Biologics, Inc.3 0 0 SVRASavara, Inc.6 0 0 -
Is ADMA or SVRA More Risky?
ADMA Biologics, Inc. has a beta of 0.485, which suggesting that the stock is 51.502% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock ADMA or SVRA?
ADMA Biologics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ADMA or SVRA?
ADMA Biologics, Inc. quarterly revenues are $134.2M, which are larger than Savara, Inc. quarterly revenues of --. ADMA Biologics, Inc.'s net income of $36.4M is higher than Savara, Inc.'s net income of -$29.6M. Notably, ADMA Biologics, Inc.'s price-to-earnings ratio is 19.12x while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics, Inc. is 8.20x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ADMAADMA Biologics, Inc.8.20x 19.12x $134.2M $36.4M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
